Immune checkpoint inhibitors (ICIs) have been changing the paradigm of cancer treatment.
However, immune-related adverse effects (irAEs) have also increased with the exponential …

Immune checkpoint inhibitors (ICIs) block inhibitory molecules, such as cytotoxic T-
lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1), or its …

Conclusion Clinical decisions about cancer patients deserving immunotherapy in the current
context of the COVID-19 pandemic should be characterized by separated reflections …

Pneumocystis jiroveci remains an important fungal pathogen in immunocompromised hosts.
The environmental reservoir remains unknown. Pneumonia (PJP) results from airborne …

Immunotherapy that includes programmed cell death-1 (PD-1), programmed cell death-
ligand 1 (PD-L1) and cytotoxic T lymphocyte antigen 4 (CTLA-4) inhibitors has …

Melanoma is the most aggressive and deadliest type of skin cancer. In the last 10 years,
immune checkpoint blockades (ICBs) including PD-1/PD-L1 and CTLA-4 inhibitor has been …

Background: Immune checkpoint inhibitors (ICIs), such as programmed cell death protein 1
(PD-1)/programmed death-ligand 1 (PD-L1), have been widely applied in clinical and …

Radiation-induced lung injury (RILI) is a form of radiation damage to normal lung tissue
caused by radiotherapy (RT) for thoracic cancers, which is most commonly comprised of …

Melanoma patient remains a challenging for the radiologist, due to the difficulty related to the
management of a patient more often in an advanced stage of the disease. It is necessary to …

Background Immune checkpoint inhibitors (ICIs) have improved survival and are
increasingly used for non-small cell lung cancer. However, use may be limited by immune …